Lian Liu, Song Li, Zimin Liu, Yanguo Liu, Kainan Li, Lei Cong, Fangli Cao, Aina Liu, Haiyan Liu, Ling Li, Linli Qu, Yi Zhai, Feng Wang, Jisheng Li, Duanbo Shi, Jiahui Chu, Di Zhang, Zhaodi Nan, Qian Xu, Shulun Nie. "Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4059